Prevention and control of meningococcal disease: Updates from the Global Meningococcal Initiative in Eastern Europe

Bai X., Borrow R., Bukovski S., Caugant D. A., Culic D., Delic S., ...Daha Fazla

JOURNAL OF INFECTION, cilt.79, sa.6, ss.528-541, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 79 Sayı: 6
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.jinf.2019.10.018
  • Dergi Adı: JOURNAL OF INFECTION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.528-541
  • Anahtar Kelimeler: Antibiotic resistance, Bacterial meningitis, Conjugate vaccine, Eastern Europe, High-risk groups, Immunization program, Meningococcal disease, Neisseria meningitidis, Polysaccharide vaccine, Refugees, B VACCINE 4CMENB, RESISTANT NEISSERIA-MENINGITIDIS, PREDICTED STRAIN COVERAGE, SEROGROUP-B, REDUCED SUSCEPTIBILITY, CONJUGATE VACCINE, UNIVERSITY-STUDENTS, ROUTINE INFANT, OBSERVER-BLIND, C DISEASE
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) world-wide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,00 0 persons per year. Predominating serogroups are B and C, followed by A, and cases attributable to serogroups W, X and Y are emerging. Available vaccines differ between countries, are generally not included in immunization programs and provided to high-risk groups only. Available vaccines include both conjugate and polysaccharide vaccines; however, current data and GMI recommendations advocate the use of conjugate vaccines, where possible, due to the ability to interrupt the acquisition of carriage. Ongoing carriage studies are expected to inform vaccine effectiveness and immunization schedules. Additionally, IMD prevention and control should be guided by monitoring outbreak progression and the emergence and international spread of strains and antibiotic resistance through use of genomic analyses and implementation of World Health Organization initiatives. Protection of high-risk groups (such as those with complement deficiencies, laboratory workers, migrants and refugees) is recommended. Crown Copyright (C) 2019 Published by Elsevier Ltd on behalf of The British Infection Association.